Despite advancements in treatment and prevention, patients with established atherosclerotic cardiovascular disease (ASCVD) still have particularly high risk of having another heart attack, stroke, or ...

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.

The Family Heart Foundation, a non-profit research and advocacy organization to lead research and education, focusing on genetic dyslipidemias, has launched the Lp(a) AW(a)RE initiative to engage key ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...

Discover Enlicitide, a new daily pill for genetic high cholesterol (HeFH). A recent trial shows it lowers bad LDL cholesterol ...